AAP
CTNM

Arax Advisory Partners’s Contineum Therapeutics CTNM Stock Holding History

Arax Advisory Partners’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-8
Closed -$94 – 4589
2025
Q3 		$94 Buy
+8
New +$64 ﹤0.01% 3501

Other funds holding CTNM

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Arax Advisory Partners's CTNM Position: Q4 2025 in Review

Arax Advisory Partners sold out of Contineum Therapeutics (CTNM) in Q4 2025, closing a stake of 8 shares — an estimated $94 sold.

Arax Advisory Partners first reported a position in CTNM in Q3 2025 and held it in 1 quarter. The position peaked at $94 in Q3 2025. 80 funds tracked by Wall St. Rank hold CTNM as of Q4 2025.

  • Arax Advisory Partners reported no remaining Contineum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Arax Advisory Partners sold 8 Contineum Therapeutics shares in Q4 2025, an estimated $94.
  • Arax Advisory Partners first reported a position in Contineum Therapeutics in Q3 2025 and held it in 1 quarter.
  • Arax Advisory Partners's Contineum Therapeutics position peaked at $94 in Q3 2025.
  • 80 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q4 2025.

Based on Arax Advisory Partners's 13F filing for Q4 2025, filed 13 Feb 2026.